Abbott has received two new clearances from the US Food and Drug Administration (FDA) for its CentriMag acute circulatory support system.

The company secured clearances for the CentriMag blood pump and the CentriMag pre-connected pack, supporting the life support system’s ability to provide longer-term support to patients in need.

The CentriMag blood pump for use with the CentriMag system is now approved to provide longer-term support to critically ill adults who require extracorporeal membrane oxygenation (ECMO) to save their life. ECMO is a form of artificial life support provided to patients whose hearts and lungs are not functioning correctly.

The blood pump was previously indicated for use for only six hours. The approval for longer-term support provides additional flexibility and time for physicians to make critical decisions for ensuring the best outcomes for their patients.

The new CentriMag pre-connected pack offers various pre-connected components of the CentriMag system including a blood pump and oxygenator to enable quick deployment of the life support system in emergency situations.

It has been approved for cardiopulmonary support lasting less than six hours to enable more efficient critical care management.

Advocate Christ Hospital and Medical Center cardiothoracic surgeon Antone Tatooles said: “Life support technology is a critical tool for physicians as we assess the next steps for our sickest patients.

“The need for long-term support from systems like the Abbott CentriMag pump was vital during the COVID-19 pandemic.”

The CentriMag pump is designed for use in intensive care units to temporarily replace the function of the heart. It pumps blood from the body into a series of devices where oxygen is added. A machine is used to pump the oxygenated blood back into the body.

Abbott heart failure business global medical affairs divisional vice-president Robert L Kormos said: “With CentriMag, our mission has always been to transform the treatment of advanced cardiac and respiratory conditions to improve clinicians’ ability to most effectively manage their sickest patients.

“With the two new FDA clearances, physicians can deploy support in fewer steps and are provided more time to get their patients the necessary treatment during a critical window.”